GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4Results posted

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION [EGP]: Can the Glucagon-like Peptide-1 [GLP-1] Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Lead sponsor

The University of Texas Health Science Center at San Antonio

Assets

Exenatide / GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

107

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 21-45•HbA1c 7-10.5%

Primary endpoint

•EGP From Baseline to Post-oral Glucose Load

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03331289

Org study IDHSC20170582H

Secondary IDR01DK107680

Timeline

Milestones

Study first posted2017-11-06actual

Study start2018-02-28actual

Primary completion2022-03-31actual

Study completion2022-11-04actual

Last update posted2023-07-24actual

Results first posted2023-07-24actual

Assets

Investigational agents

Exenatide GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Health Status: Type 2 Diabetes Mellitus according to ADA criteria (subjects must be in good general health as determined by physical exam, medical history, blood chemistry-CBC, TSH, T4, EKG and urinalysis)

•BMI: 21-45kg/m

•HbA1C>7.0% and <10.5%

•Medication: Drug naïve and/or on a stable dose of metformin and/or sulfonylurea (more than 3 months)

Exclusion criteria

•Health Status: Type 1 Diabetics

•Proliferative diabetic retinopathy

•Plasma Creatinine greater than 1.4mg/dL in females or greater than 1.5mg/dL in males, or 24 hour urine albumin excretion greater than 300mg/dL

•Medication: Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea)

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Change in EGP From Baseline to Post-oral Glucose Load.

Time frame:From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]

change from baseline, improvement

Posted result

Group	Value (mean), mg/kg.min	95% CI
Placebo	-0.03	—
Exenatide	-0.18	—
Dapagliflozin	0.14	—
Exenatide and Dapagliflozin	-0.08	—

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Diabetes care2022 Jun 2PMID35235659doi:10.2337/dc21-1798via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.